Summary
The FIRE Cancer Act of 2025 allocates $700 million for firefighter cancer prevention programs, specifically funding multi-cancer early detection tests. This creates a direct market for diagnostic companies offering these tests and establishes a joint research program between FEMA and CDC.
Market Implications
The FIRE Cancer Act of 2025 creates a new, dedicated market for multi-cancer early detection tests, valued at $700 million. This directly benefits diagnostic companies like $LH and $DGX, and technology providers such as $ILMN and $GH, by increasing demand for their services and products. The maximum reimbursement of $1,750 per test provides a clear pricing signal for these services.
Full Analysis
The FIRE Cancer Act of 2025, H.R. 1610, amends the Federal Fire Prevention and Control Act of 1974 to establish cancer prevention programs for firefighting personnel. This bill directly authorizes $700,000,000 for grants under subsection (c)(3)(F) to fund multi-cancer early detection testing or other preventative tests for firefighters. It also sets a maximum reimbursement of $1,750 per multi-cancer early detection test. This represents a new, dedicated funding stream for specific diagnostic services.
The funding flows directly from FEMA grants to fire departments and emergency medical services organizations, which will then procure multi-cancer early detection tests. Companies specializing in diagnostic testing, particularly those with multi-cancer early detection platforms, are positioned to capture this market. The bill also establishes a joint cancer research program between FEMA and the CDC, where anonymized test results will be shared to study cancer trends in firefighters. This research component could further drive demand for specific testing technologies.
Historically, federal funding for specific health initiatives has created direct market opportunities. For example, when the Affordable Care Act (ACA) was implemented, it expanded coverage for preventative services, leading to increased utilization of diagnostic tests. While not a direct comparison to a specific bill, the consistent federal investment in health programs has historically benefited diagnostic and pharmaceutical companies. The $700 million authorization is a new, dedicated budget line item for this specific type of testing.
Specific winners include companies developing and marketing multi-cancer early detection tests. $LH (LabCorp) and $DGX (Quest Diagnostics) are major diagnostic providers that could expand their offerings or see increased demand for existing tests. Companies like $ILMN (Illumina) and $GH (Guardant Health), which are involved in advanced genomic sequencing and liquid biopsy technologies used in multi-cancer detection, also stand to gain as their technologies become more widely adopted through this funding. There are no clear losers, as this bill creates a new market rather than restricting an existing one.
This bill was introduced in the House and referred to the Committee on Science, Space, and Technology. The next step is committee consideration, including hearings and potential markups. If it passes committee, it moves to a full House vote. Given its bipartisan sponsorship (Gottheimer D-NJ, Bacon R-NE, Gillen D-WI, Lawler R-NY), it has a reasonable chance of advancing. The $700 million authorization indicates a significant commitment if enacted.